Seres Therapeutics, Inc.
MCRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | -3,704% | – | – | – |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 2,639% | – | – | – |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 2,337.3% | – | – | – |
| EPS Diluted | 0.935 | -2.271 | 3.75 | -1.808 |
| % Growth | 141.2% | -160.6% | 307.5% | – |
| Operating Cash Flow | $0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | $0 | -$0 |